Live webinar on the use of generics, biosimilars and non-biologic complex drugs for multiple sclerosis

Save the date!

The webinar will take place in Zoom and it will host two similar sessions:

• An English session (translation in Spanish) on June 11th from 4 PM to 5 PM
• A German session (translation in English). The exact date for this session will be confirmed shortly.

Because multiple sclerosis (MS) usually has an onset in early adulthood and is a progressive disease, the economic burden is substantial, and disease-modifying treatments (DMTs) constitute a large proportion of healthcare costs. The use of generic versions (of synthetic drugs), biosimilars (for biologics) or follow-on versions of non-biologic complex drugs (NBCDs) can reduce the overall cost of MS care and improve patient access.

In Europe, there are robust regulatory processes and effective oversight for generic, biosimilar and follow-on NBCDs of DMTs so that these agents can be considered interchangeable with the originator product. Physicians caring for patients with MS need to familiarise themselves with the evidence so that they can have informed conversations with their patients about the potential use of these agents.

Should you have specific questions, you would like to see discussed, please share them with learning@paradigms.foundation

OUR SPEAKERS

Celia Oreja Guevara, Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos, Madrid

Professor Celia Oreja-Guevara is Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos, Madrid and Professor of Neurology at the University Complutense, Madrid, Spain. Professor Oreja-Guevara’s research interests centre on family planning, menopause, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. Neuromyelitis optica (NMO) is among her other therapy areas of interest, and Professor Oreja-Guevara is actively involved in the evaluation of new drugs for the treatment of MS and NMO.

Thomas Berger, Professor of Neurology and Chair of the Dept. of Neurology at the Medical University of Vienna.

Thomas Berger, MD, MSc, FEAN, is Professor of Neurology and Chair of the Dept. of Neurology as well as Chair of the Comprehensive Center for Clinical Neurosciences & Mental Health at the Medical University of Vienna, Austria.
Scientific interests regard neuroimmunology, especially inflammatory demyelinating CNS disorders with a dedicated focus on body-fluid and imaging biomarker research in multiple sclerosis, NMOSD and MOGAD.

Moderator: Stefaan De Corte, General Manager, ParadigMS

REGISTRATION

Registration is necessary and can be completed by clicking the following button:

Please note: this is a live webinar primarily for neurologists from Europe, the Middle-East and North-Africa. Should you not fit this category and should we reach maximum capacity (100), we might cancel your registration.